Right Energy, Right Time
with Precision Shock Technology
Gallant™ & Entrant™ ICDs and CRT-Ds
Gallant and Entrant ICDs & CRT-Ds
Timing is everything when shocking a patient out of VF. Precision Shock Technology delivers the right energy within the right time for greater first-shock success.1-9
Clinical data demonstrated patients programmed with optimized Precision Shock Technology significantly improved first-shock success by 14%.1
of first-shocks were successful with optimized Precision Shock Technology.1
*median % of shock success evaluated paired, intra-patient differences in shock success rate and delivered energy were evaluated.
Right Energy. Right Time. For greater first-shock success.1-5
Energy delivered within the tissue time constant of 3-5 ms is the most effective for conversion.2-5
Any energy outside this response window is wasted.
Proven to provide narrower QRS and reduce heart failure hospitalizations.10, 11
SyncAVTM CRT technology delivers nearly 2x the median acute QRSd improvement compared to off-the-shelf AV delays, regardless of pacing mode.10 HF hospitalization rates significantly reduce by 22% at 2 years with SyncAV CRT technology ON vs OFF.11
.png)
BiV = BiV-pacing
MPP = MultiPoint pacing
LVSS = LV-only single site pacing
LVMPP = LV-only MultiPoint pacing
Real-World Clinical Evidence
41% reduction in heart
failure readmissions12
34% reduction in all-cause
hospitalization readmissions12
23% reduction ($1,135)
in 2-year cost12
$4,031
lifetime savings per
CRT patient12
Potential to Save More Lives with Therapy Assurance.
VF Therapy Assurance is the only technology to provide an additional safety net for difficult-to-detect ventricular arrhythmias. Without VF Therapy Assurance, ventricular tachyarrhythmias with low and varying signal amplitudes may not be successfully identified.13, 14
of patients who received HV therapy due to VF Therapy Assurance's enhanced detection would have been otherwise untreated for potentially life-threatening arrhythmias.13
.png)
MR Conditional with LBB Lead*
MR Conditional with UltiPace™ Pacing Lead in the left bundle branch (LBB) area when used in the LV IS-1 port.
With Abbott-exclusive No Wait 1.5T and 3T MRI, ensure your patients can get the scans they need, when they need it.‡
Abbott's MRI-ready solutions ensure no loss of CRT therapy for your patients in full-body scans and allows for MRI Timeout programming.**
References
- Improved ICD Shock Efficacy using Programmable Pulse Width. Michael Katcher, MD; Kevin Davis, BS; Nima Badie, PhD; Luke C. McSpadden, PhD; Ulrika Birgersdotter-Green, MD; Jacqueline Joza, MD; Robert Schaller, MD; Gabriel Mouchawar, PhD. Heart Rhythm Society Conference. April 24-27, 2025
- Swerdlow C., Brewer J., Kass R., Kroll M. (1997). Application of models of defibrillation to human data: Implications for optimizing implantable defibrillator capacitance. Circulation 96(9),pgs. 2813-2822.. DOI: 10.1161/01.CIR.96.9.2813
- Ellenbogen K., Wilkoff, G., Kay G., Lau C. (2007). Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy (3rd ed.). Elsevier Saunders; pg 542-547. ISBN-13: 978-1- 4160-2536-8
- Kawata, U., Birgersdotter- Green, U. (2018). Ventricular Fibrillation and Defibrillation, Encyclopedia of Cardiovascular Research and Medicine. Elsevier, pgs 674- 682. ISBN 9780128051542. DOI: 10.1016/B978-0-12- 809657-4.99764-3
- Efimov, I., Kroll, M., Tchou, P. (2009). Cardiac Bioelectric Therapy. Springer, pgs. 468- 472. ISBN 978-0-387-79403- 7
- Kroll, M., Lehmann, M. (1996). Implantable Cardioverter Defibrillator Therapy. Kluwher Academic Publishers, pgs. 68 -69.
- Gold, M., Shorofsky S. (1997). Strength-duration relationship for human transvenous defibrillation. Circulation 96:3517-3520.
- Kroll, M., Swerdlow, C. (2007). Optimizing defibrillation waveforms for ICDs. Journal of Interv Card Electrophysiol 18:247-263. DOI 10.1007/s10840-007- 9095-z
- Doshi, S., Pittaro, M., Reeves, M., Boyce, K., Payne, J., Kroll, M., Graumann, R., Oza, A., Val- Mejias, J. (2012). Efficacy of Tuned Waveforms Based on Different Membrane Time Constants on Defibrillation Thresholds: Primary Results from the POWER Trial. PACE Vol. 00. Pg. 8. DOI: 10.1111/j.1540- 8159.2012.03500.
- Thibault B, Waddingham P, Badie N, Mangual JO, McSpadden LC, Betts TR, Calò L, Grieco D, Leyva F, Chow A. Acute Electrical Synchronization Achieved With Dynamic Atrioventricular Delays During Biventricular and Left Ventricular MultiPoint Pacing. CJC Open. 2024 Nov 8;7(2):166-175. doi: 10.1016/j.cjco.2024.11.003
- Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://www.escardio.org/Sub-specialty-communities/European-Heart-Rhythm-Association-%28EHRA%29/Research-and-Publications/EHRA-Essentials-4-You#lbt. Accessed May 15, 2020
- Varma N, Hu Y, Connolly AT, et al. Gain in real-world cardiac resynchronization therapy efficacy with SyncAV dynamic optimization: Heart failure hospitalizations and costs. Heart Rhythm. 2021;18(9):1577-1585. doi:10.1016/j.hrthm.2021.05.006
- Wilkoff BL, Sterns LD, Katcher MS, et al. Novel ventricular tachyarrhythmia detection enhancement detects undertreated life-threatening arrhythmias. Heart Rhythm O2. 2022;3(1):70-78. doi:10.1016/j.hroo.2021.11.009
- Stroobandt RX, Duytschaever MF, Strisciuglio T, et al. Failure to detect life-threatening arrhythmias in ICDs using single-chamber detection criteria. Pacing and clinical electrophysiology : PACE. 2019;42(6):583-594. doi:10.1111/pace.13610
- Calò L, De Ruvo E, Kolb C, Janmohamed A, Marques P, Defaye P, Marquie C, Piot O, Grammatico A, Lee K, Lin W, Burri H, Sperzel J, Thibault B, Rinaldi C, Leclercq C. Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses. Europace. 2024 Nov 1;26(11):euae259. doi: 10.1093/europace/euae259. Erratum in: Europace. 2025 Feb 5;27(2):euaf022. doi: 10.1093/europace/euaf022.
- Device IFUs: Abbott Tachycardia Devices Help Manual (ARTEN600307504A), Medtronic manuals (Evera XT, Amplia, Cobalt XT, and Crome), Boston Scientific manuals (NG4 Tachy ICD, NG4 Tachy CRT-D), and Biotronik (Rivacor ICDs and CRT-Ds, Acticor ICDs and CRT-Ds).
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
‡ No minimum length of time requirement between implant and MRI scan. Stability of pacing capture thresholds is required prior to MRI scan
* Not all models of these devices may be commercially available in all regions.
** MR conditional with our UltiPace™ Pacing Lead in the left bundle branch area (LBBA) using LV IS-1 port with Gallant™, Neutrino NxT™ and Entrant™ CRT-D models. For additional information about specific MR Conditional ICDs, leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to Abbott MRI-Ready Systems Manual at manuals.eifu.abbott.
*** No Loss of CRT therapy only applies to applicable Gallant and Neutrino Nxt Models.
These device models may not be commercially available in all markets.
Gallant™ VR ICD, Gallant™ DR ICD, Gallant™ HF CRT-D, Entrant™ VR ICD, Entrant™ DR ICD and Entrant™ HF CRT-D are a CE marked medical devices. CE 0123. Legal Manufacturer: Abbott Medical – 15900 Valley View Court, Sylmar, California 91342, U.S.A
MAT-2509530 v1.0 | Item only approved for OUS use